Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily and has been shown to induce apoptosis in cancer cells but not normal cells. TRAIL triggers apoptosis through binding to its receptors DR4 and KILLER/DR5. Chemo or radiotherapy induces apoptosis through activation of p53 in response to cellular damage, whereas TRAIL induces apoptosis independent of p53. Mutations or deletions of p53 occurred in more than half of human tumors confer resistance to chemo-radiotherapy. Treatment of TRAILresistant tumors with agents targeting death receptors, intrinsic Bcl-2 family members, inhibitor of apoptosis proteins or PI3K/Akt pathway restores the sensitivity to TRAIL-induced apoptosis. Combination of rhTRAIL or the agonist antibody for TRAIL receptor with conventional chemotherapeutic agents results in enhanced efficacy in preventing tumor progression and metastasis. Therefore, the rational design of TRAIL-based therapy combining with other modality that either synergizes to apoptosis induction or overcomes the resistance represents a challenging strategy to achieve the systemic tumor targeting and augment the antitumor activity of cancer therapeutics. Oncogene (2008) 27, 6207-6215; doi:10.1038 /onc.2008 Keywords: tumor necrosis factor-related apoptosisinducing ligand; TNF receptor superfamily; DR4; KILLER/DR5; apoptosis; cancer therapy Cancer is the second leading cause of death in the world. Cancer researchers are jointly contributing to groundbreaking effort to accelerate progress against cancer. Most recently, the American Association of Cancer Research (AACR) issued a call for the creation of a collaborative, translational 'Dream team' to fight against cancer. Up to date, the main approach in treating cancer besides surgery is the chemo or radiotherapy. Tumor cell apoptosis plays an essential role in modulating sensitivity to chemo or radiotherapy. Deregulated apoptosis not only plays a key role in the pathogenesis and progression of cancer by allowing tumor cells to survive beyond a normal lifespan, but also leads to resistance to chemo or radiotherapy. Some chemo or radiotherapy works effectively in killing some cancer cells through the intrinsic apoptotic pathway engaged by the activation of p53 in response to DNA damage, but many tumors in which p53 is mutated or deleted are less sensitive to chemo or radiotherapy (Lowe et al., 1993a (Lowe et al., , b, 1994 . Moreover, the chemo or radiotherapy induces apoptosis in both cancer and normal cells and therefore possesses severe toxic side effects. In recent years, efforts have been focused on the development of biological mechanism-based strategies that might exert high tumor selectivity and enhanced antitumor activity. Members of the tumor necrosis factor (TNF) superfamily including Fas ligand, TNF and TNF-related apoptosis-inducing ligand (TRAIL) have been identified as important targets for cancer biological therapy (Wiley et al., 1995; Ashkenazi, 2002) . Administration of Fas Ligand or TNF can induce apoptosis in different cancer cells but cause severe toxicity to liver, therefore hampering their application in the clinic. TRAIL appears as a promising cancer therapeutic agent and induces apoptosis in a wide variety of tumor cells, without causing toxicity to normal cells (Ashkenazi et al., 1999; Walczak et al., 1999) . Importantly, TRAIL triggers apoptosis in cancers, regardless of p53 status, and therefore is an attractive agent especially for cancer cells in which p53 function has been inactivated, because it helps to circumvent the resistance to chemo or radiotherapy. This review summarizes the current understanding of the TRAIL/TRAIL receptor signaling pathway and the progress of the translational aspects of TRAIL-based therapy as novel cancer therapeutics.
The structure and properties of TRAIL
The TRAIL gene is located on chromosome 3 and spans approximately 20 kb, which is composed of five exons and four introns. The TRAIL transcripts are detected in various human tissues, most predominately in spleen, lung and prostate (Wiley et al., 1995) . TRAIL is a type II transmembrane protein and consisted of 281 and 291 amino acids in the human and murine forms, respectively, sharing 65% amino-acids identity. TRAIL has an N-terminal domain, which is not conserved across the family members, while the C-terminal domains show significant conservation. The percent identity to the most related members of the TNF ligand family, Fas ligand, TNF-a, Lt-a and LT-b, is 28, 23, 23 and 22% respectively (Wiley et al., 1995) . TRAIL is the only protein of the TNF family that contains cysteine residue, Cys230, which allows the interaction among three molecules of TRAIL (Figure 1 ). The zinc ion bound by the cysteines in the trimic ligand is essential for trimerization and optimal biological activity (Hymowitz et al., 1999; Mongkolsapaya et al., 1999) . After cleavage of the extracellular C-terminal portion of the TRAIL from the cell surface, TRAIL can be released by the cells as a soluble molecule. TRAIL is not expressed at the freshly isolated human T cells, B cells, dendritic cells (DCs) and natural killer (NK) cells, whereas only a portion of mouse NK cells express TRAIL at the cell surface. A polyhistidine-tagged soluble form of human TRAIL (114-281) was biologically active. TRAIL fusion protein (termed LZ-TRAIL) in which the extracellular region of the ligand (95-281) is linked to an exogenous, modified leucine zipper that drives the trimerization shows higher biological activity. Addition of dithiothreitol in the purification process enhances hyper-oligomerization of TRAIL and results in high potency in apoptosis induction (Kim et al., 2004b) . After administration of LZ-TRAIL intravenously into mice, a maximal serum concentration of TRAIL was detected 5 min after the injection and the extended distribution half-life was 1.3 h and an elimination halflife was 4.8 h (Walczak et al., 1999) . The half-life of the soluble form of TRAIL (114-281) in non-human primate (chimpanzee) is 32 min (Ashkenazi et al., 1999) . Figure 1 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors. The crystal structures of complexes between TRAIL and its receptor DR5. The TRAIL trimer is indicated as ribbon in blue, and the three clustered receptors are drawn as tubes in yellow (Hymowitz et al., 1999) . (a) In this orientation, the membrane of the receptor-containing cells is at the bottom. (b) View of the complex from the top. There are two proapoptotic and three antiapoptotic receptors for TRAIL in human (c). In mice, only one proapoptotic and two antiapoptotic TRAIL receptors were found (d).
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TRAIL receptors
Tumor necrosis factor-related apoptosis-inducing ligand forms homotrimers and induces apoptosis through interacting with three cross-linked receptor molecules on the surface of the target cells (Figure 1 ). TRAIL mainly interacts with two types of receptors: death receptors triggering apoptosis and decoy receptors preventing apoptosis (Figure 1 ). To date, five human TRAIL receptors have been identified including DR4/TRAIL-R1 (Pan et al., 1997b) , DR5/TRAIL-R2/ KILLER (Pan et al., 1997a; Sheridan et al., 1997; Walczak et al., 1997; Wu et al., 1997) , TRID/DcR1/ TRAIL-R3 (Degli-Esposti et al., 1997b; Pan et al., 1997a; Sheridan et al., 1997) and TRAIL-R4/DcR2 (Degli-Esposti et al., 1997a; Marsters et al., 1997) , as well as the soluble receptor called osteoprotegerin (Emery et al., 1998) . In mice, only one death receptor (mDR5) which is homologous to human KILLER/DR5 and two decoy receptors (mDcR1 and mDcR2) have been found (Wu et al., 1999; Schneider et al., 2003) . DR4 and KILLER/DR5 are type I transmembrane proteins containing an intracellular death domain that engages the apoptotic machinery upon TRAIL binding, whereas the other receptors either act as decoys or transduce antiapoptotic signals. DcR1 and DcR2 share close homology to the extracellular domains of the agonistic receptors DR4 and DR5. DcR2 has a truncated, nonfunctional cytoplasmic death domain, whereas DcR1 exists on the membrane as a glycophospholipid-anchored protein lacking of a cytosolic region. The trimerization of the death receptor is required for the recruitment of an adaptor protein Fas-associated death domain (FADD) and the formation of deathinducing signal complex (DISC) through recruiting the initiator caspase 8 or 10 (Bodmer et al., 2000; Kischkel et al., 2000; Sprick et al., 2000) . Although TRAIL binds to the decoy receptors, FADD is not recruited and the apoptosis is not triggered. It has been suggested that DcR1 or DcR2 differentially inhibits the TRAILmediated DR5-DISC formation; whereas DcR1 prevents the assembly of DISC by titrating TRAIL, DcR2 is corecruited with DR5 within the DISC and impaired initiator caspase activation. Furthermore, DcR2 interacts with DR5 in the native DISC in a TRAILdependent manner and prevents DR4 corecruitment to DR5 (Me´rino et al., 2006) .
TRAIL/TRAIL receptor signaling pathway
There are two main apoptotic pathways to initiate the programmed cell death including the extrinsic pathway and the intrinsic pathway, and both are utilized depending on the different stimuli ( Figure 2 ). Extrinsic pathway triggers apoptosis through engagement of the cell surface death receptors DR4 and/or DR5 by their ligand TRAIL. The binding of TRAIL to death receptors leads to the trimerization of the receptors and the recruitment of FADD. Subsequently, FADD recruits the initiator caspase 8 or 10 leading to the assembly of DISC, where the initiator caspases are autoactivated by proteolysis. Activated caspase 8 or 10 then cleaves the effector caspase 3, which in turn results in the cleavage of the death substrates. The intrinsic pathway or mitochondrial pathway induces apoptosis in response to DNA damage, hypoxia and oncogene overexpression. This pathway involves the activation of proapoptotic Bcl-2 family members Bax and Bak in the mitochondrion and is negatively regulated by the antiapoptotic Bcl-2 family members Bcl-2 and Bcl-xL Wei et al., 2001) . Recently, antiapoptotic Bcl-2 family member Mcl-1 was found to play an essential role in TRAIL-induced apoptosis (Ricci et al., 2007; Kim et al., 2008a, b) . Activation of Bax and/or Bak results in the changes of mitochondrial membrane potential and leads to the release of the cytochrome c. In the cytosol, cytochrome c binds to APAF-1, forming the apoptosome in which the caspase 9 is activated and in turn results in the activation of caspases 3, 6 or 7 (Zou et al., 1997) . As a sensor of the cellular stress, p53 is a critical initiator for the intrinsic pathway. In type I cells, activation of caspase 8 is sufficient to directly activate the downstream effector caspases leading to apoptosis. The extrinsic pathway in type I cells is independent of mitochondria and could not be blocked by Bcl-2, whereas in type II cells, the amount of activated caspase 8 or 10 is not enough to trigger the activation of effector caspases, and consequently, the apoptotic program needs the amplification loop through the mitochondrial pathway activated by the cleavage of bid by caspase 8 (Ozoren et al., 2000; Burns and El-Deiry, 2001; Ozo¨ren and El-Deiry, 2002) . Tumor necrosis factor-related apoptosis-inducing ligand signaling does not only lead to the activation of effector caspases and initiation of apoptosis, but also induce non-apoptotic pathway, including the activation of nuclear factor-kB (NF-kB), JNK or p38 mitogenactivated protein kinase (MAPK) pathways (Marsters et al., 1996) (Figure 2) . It has been shown that NF-kB was activated through engagement of DR4 or DR5 upon TRAIL binding and that the receptor-interacting protein is present in the DR4/5-DISC and mediates the TRAIL-induced IKK activation (Lin et al., 2000) . Recently, the activated NF-kB by TRAIL was found to transactivate the antiapoptotic Mcl-1, therefore providing the survival advantage of the cells, which the proapoptotic molecules dictate the fate of the cells when the intrinsic pathway is intact (Hall and Cleveland, 2007; Ricci et al., 2007) . It has been reported that TRAF2 in the DR4/5-DISC upon ligand binding is essential for the activation of JNK (Lin et al., 2000) and that the activation of JNK by TRAIL promotes the phosphorylation of the antiapoptotic Bim, leading to the activation of caspases and initiation of apoptosis (Corazza et al., 2006) .
The physiological role of TRAIL and its receptors
Tumor necrosis factor-related apoptosis-inducing ligand is a cytokine that is expressed by effector lymphocytes TRAIL signaling in cancer therapy S Wang and plays a role in shaping and regulating the immune system. TRAIL knockout mice are viable and display no apparent hematological and reproductive disorders (Cretney et al., 2002) . The expression level of TRAIL is extremely low in the freshly isolated lymphocytes. Only a small set of murine NK cells express detectable TRAIL and it appears most likely that the expression of TRAIL on the liver NK cells is regulated by the secretion of interferon (IFN)-g from the NK cells in an autocrine manner (Takeda et al., 2001) . It has been shown that stimulation of the DCs with IFN-b results in the expression of TRAIL on the DCs, therefore enhancing the cytotoxicity of DCs to tumor cells (Liu et al., 2001) . Therefore, TRAIL might play a role in regulating the innate immune response involving the IFNs, NK cells and DCs (Smyth et al., 2003) . Recently, TRAIL-R knockout mice studies indicated that TRAIL-R is a negative regulator of innate immune response and that loss of TRAIL-R leads to the increased levels of IFN-a, -g and interleukin-12 and activation of NF-kB (Diehl et al., 2004) . Furthermore, TRAIL contributes to the host immunosurvelliance against primary tumor development and metastasis. It has been suggested that TRAIL antimetastatic activity was restricted to liver NK cells. Both neutralizing anti-mTRAIL mAB and TRAIL knockout mice supported a direct role for NK cells expressing TRAIL in the suppression of tumor metastasis, with no metastasis occurred against the TRAIL-resistant cells examined (Takeda et al., 2001; Cretney et al., 2002) . Trauzold et al. showed that TRAIL strongly induces the expression of interleukin-8 followed by the distant metastasis of the pancreatic tumors in vivo (Trauzold et al., 2006) . More recently, it was reported that metastasis to lymph nodes was significantly enhanced in the TRAIL-R knockout mice, indicating a role of TRAIL-R in the suppression of tumor metastasis (Grosse-Wilde et al., 2008) . TRAIL can boost the host responses to the tumor and somehow change the tumor microenvironment for enhanced antigen presentation and tissue infiltration. Some studies showed that IFN-g induction by T cells is essential for the tumor infiltration and migration and that IFN-g has to act on the tumor stromal cells (Blankenstein, 2005) . The IFN-g-induced expression of TRAIL may lead to greater leukocyte infiltration in the tumor. TRAILsensitive tumor cells may become resistant by challenging interaction with TRAIL-expressing, tumor filtrating immune cells or stromal cells (Mace et al., 2006) . Hypoxic environments, often present in solid tumors, are known to induce the upregulation of hypoxia-inducible factor-1a, which in turn leads to the induction of the hypoxia-response genes including Figure 2 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor signal-transduction pathway. Upon binding of TRAIL or the agonist antibody to DR4 or DR5, the death receptors are clustered leading to the formation of deathinducing signal complex (DISC) through recruitment of Fas-associated death domain (FADD), and subsequently results in the autoactivation of caspase 8. In type I cells, caspase 8 activation is sufficient to induce apoptosis through activating the downstream effector caspases. Whereas in type II cells, apoptosis induction needs the amplification loop involving the mitochondrial pathway engaged by the truncated Bid, which was cleaved by activated caspase 8. In addition, engagement of TRAIL receptors leads to the formation of the second complex involving the receptor-interacting protein (RIP), which links the receptor stimulation with the nuclear factor-kB (NF-kB) activation. A third complex contains TRAF2, which couples the receptor activation to the JNK activation. TRAIL induces the activation of NK-kB, which in turn transactivates Mcl-1 or c-IAP2 leading to the inhibition of apoptosis, whereas JNK activation promotes the phosphorylation of Bim and results in apoptosis through the mitochondrial pathway. Myc directly transactivates DR5 or suppresses the transcription of c-FLIP, and alternatively decreases the expression of Mcl-1 and c-IAP2 by blocking NF-kB, therefore enhancing TRAIL-induced apoptosis or overcoming TRAIL resistance.
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S Wang vascular endothelial growth factor and subsequently promotes tumor angiogenesis and metastasis (Kaelin, 2007) . A hypoxic environment has been shown to confer the resistance to TRAIL-induced apoptosis in TRAILsensitive tumors (Kim et al., 2004a) . In addition to the role of TRAIL in tumor immunosurvelliance, TRAIL has also been implicated in regulating the autoimmunity. Several studies reported the increased serum level of soluble TRAIL in patients with systemic lupus erythematosus (Lub-de Hooge et al., 2005) . It has also been found that the levels of TRAIL may serve as a potential marker in determining the sensitivity to INF treatment for human multiple sclerosis patients (Wandinger et al., 2003) .
The physiological role of TRAIL receptors remains unclear. TRAIL knockout studies showed that TRAIL-R is not involved in the embryonic development because TRAIL-R knockout mice are viable and develop normally. Loss of heterozygosity of a region on chromosome 8 where KILLER/DR5 is mapped is frequently detected in head, neck and lung carcinomas (Pai et al., 1998) . KILLER/DR5 was also found to be involved in suppressing tumor progression and determining the chemosensitivity, as silencing of KILLER/DR5 promotes tumor growth and confers resistance of the tumor cells to the treatment with 5-fluorouracil (Wang and ElDeiry, 2004 ). Walczak and colleagues showed that murine DR5 functions as metastasis suppressor and that loss of DR5 enhances the metastasis of the primary tumors to lymph nodes (Grosse-Wilde et al., 2008); DR5 deficiency also promotes susceptibility to chronic inflammation and tumorigenesis. Loss of a single allele of DR5 on the lymphoma-prone Eu-myc genetic background significantly reduces median lymphoma-free survival (Finnberg et al., 2008) . Moreover, DR5 knockout mice are resistance to ionizing radiation-induced apoptosis in the thymus and spleen, demonstrating the tissue specificity of DR5 response upon irradiation (Finnberg et al., 2005) . Recently, DR5 was found to play a role in regulating the anoikis in human colon cancer cells (Laguinge et al., 2008) .
Mechanisms of TRAIL sensitivity and resistance
Tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis effectively in a wide range of cancer cells or transformed cells, and normal cells are resistant to TRAIL. Sensitivity of TRAIL-induced apoptosis can be regulated at several levels in the apoptosis signaling pathways; however, the exact mechanism that underlies why normal cells are resistant to TRAIL remains ambiguous. It has been proposed that as compared with cancer cells, normal cells express relatively higher level of decoy receptors but it has been long debating how decoy receptors play a major role in determining the sensitivity to TRAIL between cancer cells and normal cells (Hersey and Zhang, 2001) . Epigenetic changes such as promoter hypermethylation of death receptor have been identified in small-cell lung carcinoma, and loss of the expression of death receptor and caspase 8 was found to result in the resistance to TRAIL-induced apoptosis (Hopkins-Donaldson et al., 2003) . Most recently, Ashkenazi and colleagues found that post-translational modification of death receptors plays a role in modulating the TRAIL sensitivity. Death receptor O-glycosylation by peptidyl O-glycosyltransferase GALNT14 enhances the TRAIL-induced clustering of DR4 and KILLER/DR5, leading to the activation of caspase 8. The mRNA expression of GALNT14 is correlated with the TRAIL sensitivity in pancreatic carcinoma, non-small-cell lung carcinoma and melanoma cells, suggesting that GALNT14 might serve as an excellent biomarker for screening the patients most likely to benefit from the TRAIL-based therapy (Wagner et al., 2007) .
Cellular FLICE-like inhibitory protein (c-FLIP) functions as an important inhibitor for TRAIL-induced apoptosis. Being a homolog of caspase 8, c-FLIP can bind to FADD, where it competes with procaspase 8 for the association with FADD, and therefore prevents the induction of apoptosis upon TRAIL treatment (Burns and El-Deiry, 2001) , and c-myc resensitizes Bax À/À cells to TRAIL by directly repressing the transcription of c-FLIP (Ricci et al., 2004) . c-FLIP also promotes cell survival by activating the NF-kB and ERK signaling pathways (Kataoka, 2005) .
The intrinsic pathway is essential for TRAIL-induced apoptosis especially in type II cells. The activation of proapoptotic Bcl-2 family members Bax is required for TRAIL-induced apoptosis because Bax deficiency leads to the resistance to TRAIL (Burns and El-Deiry, 2001; Deng et al., 2002; LeBlanc et al., 2002) . Mcl-1, an antiapoptotic Bcl-2 family member, was recently found to play an important role in preventing TRAIL-induced apoptosis through interacting with the proapoptotic Bcl-2 member tBid (Clohessy et al., 2006) . It has been reported that targeting inhibitor of apoptosis proteins (IAPs) sensitizes tumor cells to TRAIL-induced apoptosis (Chawla-Sarkar et al., 2004) . TRAIL sensitivity can also be regulated by the transcription factor NF-kB through transactivating the antiapoptotic molecules such as c-FLIP, Mcl-1, c-IAPs and Bcl-xL (Ravi and Bedi, 2002; Ricci et al., 2007) . Deregulation of AKT pathway leads to tumorigenesis and contributes to the resistance to cancer therapeutics including chemotherapy, radiotherapy or TRAIL treatment (Vivanco and Sawyers, 2002; Manning and Cantley, 2007) . Inhibition of PI3K/AKT pathway sensitizes tumor cells to TRAIL treatment or reverses TRAIL resistance (Pespeni et al., 2007; Shrader et al., 2007) .
Oncogen c-myc acts as an important regulator for TRAIL sensitivity. It has been found that c-myc directly transactivates KILLER/DR5 or represses the transcription of c-FLIP (Ricci et al., 2004) , therefore enhancing the sensitivity of cancer cells to TRAIL-induced apoptosis. More recently, El-Deiry and colleagues found that overexpression of c-myc in Bax À/À human colon cancer cells in which the intrinsic pathway is compromised can restore the TRAIL sensitivity. c-myc directly activates the expression of KILLER/DR5 or represses the expression of Mcl-1 and c-IAPs through blocking the activation of NFkB and subsequently resensitizes the Bax À/À cells to TRAIL (Hall and Cleveland, 2007; Ricci et al., 2007) .
Preclinical studies targeting TRAIL and its receptors
The promising property of TRAIL of its marked antitumor effects in a broad range of tumor cells without systemic toxicity has resulted in many preclinical trails. The safety profile of rhTRAIL has been evaluated in various preclinical models including cells, mice and nonhuman primates as single reagent. Recombinant TRAIL variants with different tags such as polyhistidine, Flag and leucine zippers and non-tagged native versions have been tested for the efficacy and selectivity in different models. His-tagged TRAIL specifically kills tumors but shows liver toxicity due to the aggregated forms of TRAIL (Lawrence et al., 2001) . The optimized version of TRAIL zinc pocket exerts same efficacy and selectivity without toxicity to liver. Administration of the rhTRAIL into the non-human primates (cynomolgus monkeys or chimpanzees) does not cause obvious hepatotoxic effects (Ashkenazi et al., 1999) . After a long debate on potential liver toxicity, it is becoming clear that only aggregated versions such as His-tagged or Flag tagged TRAIL are hepatotoxic. Primary human hepatocytes are resistant to other forms of TRAIL, including the stably trimerized variants and non-tagged native TRAIL. According to a large number of studies and the exciting results, Genentech and Amgen have jointly launched phase II clinical trails in non-Hodgkin's lymphoma and non-small-cell lung carcinomas with rhTRAIL (Ashkenazi and Herbst, 2008) .
Death receptor pathway can be targeted by using the agonist antibody against DR4 or DR5. Most recently, it was reported that treatment of non-small-cell lung carcinomas or colon cancer cells with Apomab, an antibody that specifically binds to human DR5 but not to other receptors, results in clustering of DR5 and the activation of caspase 8 followed by massive apoptosis (Adams et al., 2008) . The antitumor activity of Apomab has been demonstrated in the murine models bearing human colon or lung tumors. Apomab treatment causes significant tumor regression and delays in tumor regrowth or ablation. The elimination half-life of Apomab was found to be 15-20 days. Importantly, Apomab is safe and generally well tolerated. Apomab is being evaluated in phase II trails in advanced cancer patients with non-Hodgkin's lymphoma and non-small-cell lung carcinomas (Ashkenazi and Herbst, 2008) .
Mapatumumab (HGS-ETR1) is an agonist antibody to DR4 and has been demonstrated to possess remarkable antitumor activity. HGS-ETR1 inhibits tumor growth and induces apoptosis in a wide variety of tumor cell lines and xenografts (Hotte et al., 2008) . In a phase II study in patients with relapsed or refractory non-Hodgkin's lymphoma, tumor response to HGS-ETR1 was found to be 8% and the antibody was well tolerated, with minimal toxicity observed. The mean terminal elimination half-life of HGS-ETR1 was approximately 17 days, much longer than the half-life of rhTRAIL . Combination of HGS-ETR1 with conventional chemotherapeutic agents shows augmented antitumor activity in human tumor cells and mouse xenografts models (Marini et al., 2006) .
TRAIL-based combinatorial therapy
Tumor necrosis factor-related apoptosis-inducing ligand resistance has been found in some of the tumor cells such as breast and lung cancers bearing mutations in DR4 or DR5, and the Bax-deficient human colon cancer cells, and therefore the application of TRAIL as single agent in the clinic has been limited. One of the most attracting properties of TRAIL is its ability to induce apoptosis independent of p53 and kill tumors in which p53 was mutated or deleted. A large amount of studies have revealed that combination of TRAIL with traditional chemo or radiotherapy significantly enhances cytotoxicity to tumors or reverses the resistance to monotherapy (Gliniak and Le, 1999; Wang and El-Deiry, 2003a, b) . Several strategies have been designed focusing on the specific targets in the extrinsic and intrinsic pathways, including death receptors, Bcl-2 family members or caspases, to enhance TRAILinduced apoptosis.
Strategies that target death receptors in combination with TRAIL-based therapy have been tested in several models. It has been shown that combination of histonedeacetylase inhibitors with rhTRAIL results in synergistic effect in tumor cells through upregulating death receptors DR4 and DR5 (Singh et al., 2005) . Interestingly, low concentration of chemotherapeutics can enhance the sensitivity to TRAIL or its agonist antibody HGS-ETR1 by accumulating the DR4 in the cell surface, therefore suggesting that low-toxic chemotherapy may be combined with TRAIL to augment efficacy in killing cancer cells (Jin et al., 2007) . Pretreatment of Bax À/À human colon cancer cells that are resistant to TRAIL with chemotherapeutic agents restores the TRAIL sensitivity, and further studies showed that chemotherapeutics resensitize Bax À/À cells to TRAIL through p53-dependent transactivation of KILLER/ DR5 (Wang and El-Deiry, 2003a) .
Targeting the antiapoptotic proteins such as Bcl-2 or IAPs in the intrinsic pathway has also been employed to enhance the TRAIL sensitivity. It has been reported that a small molecule Smac mimcs potentiates TRAILinduced apoptosis by activating caspase 8 and caspase 3 (Fulda et al., 2002; Li et al., 2004) . Combination of BH31-2 0 , the inhibitor of Bcl-xL, with TRAIL leads to the synergistic induction of apoptosis through the activation of caspase 8 and Bid (Ray et al., 2005) . The small molecule Bcl-2 inhibitor HA14-1 was capable of restoring TRAIL sensitivity in Bcl-2 overexpressing colon cancer cells (Sinicrope et al., 2004) .
Recently, the multikinases inhibitor sorafenib (BAY 43-9006) was reported to enhance TRAIL-induced apoptosis (Meng et al., 2007; Rosato et al., 2007) . Furthermore, El-Deiry and colleagues found that sorafenib treatment restored the sensitivity of Bax À/À colon cancer cells to TRAIL-induced apoptosis through reducing the levels of Mcl-1 and c-IAP2 by blocking NF-kB (Ricci et al., 2007) . Their results also indicated that combination of TRAIL with sorafenib significantly suppressed the tumor progression, making the combined TRAIL/sorafenib regimens a promising drug combination for the application in the clinic (Ricci et al., 2007) . Inhibition of prosurvival pathway such as PI3K/AKT has also been implicated in sensitizing the tumor cells to TRAIL-induced apoptosis. It was reported that pretreatment of tumor cells with the inhibitor of mTOR, rapamycin, greatly enhances TRAIL-induced apoptosis by regulating the translation of c-FLIP (Panner et al., 2005) .
Targeting several other molecules may also be of interest to increase the sensitivity to TRAIL. Blocking of NF-kB by specific inhibitor PS-1145 or AS602868 have been found to sensitize for TRAIL-induced apoptosis in pancreatic cancer (Khanbolooki et al., 2006) and myeloma (Romagnoli et al., 2007) . The heatshock protein (HSP90) inhibitor 17-AAG is now in phase I clinical trail. It has been demonstrated that combination of TRAIL with 17-AAG leads to the synergistic effect on apoptosis by downregulation of AKT and dephosphorylation of ERK . Most recently, it was reported that the low level of TRAIL in combination with antimicrotubule agents nocodazole or paclitaxel (Taxol) significantly increases the activation of caspase and augments apoptosis, suggesting that TRAIL enhances the antitumor activity of microtubule-targeting drugs (Kim et al., 2008a, b) .
Conclusions and perspective
Cancer therapeutics targeting TRAIL/TRAIL receptor signal pathway holds great promise for molecularly targeted proapoptotic anticancer therapy. rhTRAIL and the agonist antibodies for TRAIL receptors have been demonstrated to induce apoptosis in a wide variety of tumor cells and prevent tumor progression and metastasis in the preclinical models. Of particular interest is that rhTRAIL or the agonist antibody triggers apoptosis in cancer cells but not normal cells. Combination of TRAIL with traditional chemotherapeutic agents or radiotherapy enhances efficacy in killing cancers or restores the sensitivity to TRAIL. Phases I and II clinical trails with rhTRAIL and agonist antibodies are ongoing and will definitely lead to a better appreciation of targeting the TRAIL signaling pathway in cancer therapy. However, it still remains to be clarified which molecular mechanism contributes to the determination of TRAIL sensitivity between normal versus cancer cells. It will be very important to find effective ways to overcome the resistance to TRAIL or conventional chemoradiotherapy at multiple levels, including death receptors, the intrinsic proapoptotic or prosurvival pathways. Screening of the non-or low-toxic compounds found in natural food or herb, which exert synergistic effects on killing tumors in combination with TRAIL, may help to eliminate the barrier of TRAIL resistance in cancer therapy. The design that preselection of the patients most likely to benefit from rhTRAIL/agonist antibody therapy by identifying suitable biomarkers will aid to set a basis for fulfilling the promise of personalized medicine on the basis of TRAIL/TRAIL receptor pathway.
